Research

The NanoBiotechnology Group is mainly focused on the use of bioactive molecules and nanoparticles in nanomedicine & nanotechnology. It possesses a multidisciplinary philosophy, and it is led by Dr. Alvaro Somoza, an expert in the use of modified oligonucleotides and nanostructures in nanomedicine. The group deals with several research lines, centered on the use of modified oligonucleotides and proteins to create new nanomedical tools and sensors.

RESEARCH TOPICS
Dr. Alvaro Somoza´s group:

– Nanoparticles in Drug Delivery, using different nanostructures to deliver different drugs and nucleic acids for the treatment of different diseases.

– The design of new strategies for efficient editing of Uveal Melanoma and Pancreatic cancer cell lines based on the delivery ofthe CRISPR system.

– Nanosensors for multiples diseases, such as Uveal, Melanoma, Pancreatic cancer or Duchenne Muscular Dystrophy.

– Modified magnetic nanoparticles for the treatment of pancreatic cancer. (NoCanTher project)

Funded Projects

Active Projects

Red Madrileña de Nanomedicina en Imagen Molecular (RENIM)  (S2022/BMD-7403 RENIM-CM. Funding Agency: Comunidad de Madrid. PI IMDEA Nanociencia: Álvaro Somoza. Coordinator: Manuel Desco

Reactivation of anti-tumor immune cell responses by functionalized nanoparticles in melanoma. Funding Agency: Fundación Científica AECC. PI IMDEA Nanociencia: Álvaro Somoza. Coordinator: Héctor Peinado

Functionalized nanoparticles for targeted genome editing in Duchenne Muscular Dystrophy. Funding Agency: AFM-Telethon. PI IMDEA Nanociencia: Álvaro Somoza. Coordinator: Daniela Palacios

Herramientas nanobiotecnológicas para detección y tratamiento de enfermedades raras: cáncer pancreático, melanoma de úvea y distrofia muscular de Duchenne (NanoRare) ( PID2020-119352RB-I00). Funding Agency: Ministerio de Ciencia e Innovación. Pis: Álvaro Somoza & Begoña Sot.

 Desarrollo de un sensor basado en nanopartículas de oro para el diagnóstico del Virus de Papiloma Humano (SENSOR-DOC)( IND2020/IND-17517). Funding Agency: Comunidad de Madrid. PI IMDEA Nanociencia: Álvaro Somoza

Previous projects

Nanoestructuras inteligentes contra el melanoma de úvea y el cáncer de páncreas (SAF2017-87305-R)
Funding agency: Ministerio de Economía, Industria y competitividad
Preparación y Escalado de Nanopartículas Modificadas Bajo Estándares Farmacéuticos (IND2017/IND-7809)
Funding agency: Comunidad de Madrid
Nuevas aproximaciones para el tratamiento y detección de melanoma de úvea basadas en nanopartículas de oro funcionalizadas
Funding agency: Asociación Española Contra el CáncerNanomedicine Upscaling for Early
Clinical Phases of Multimodal Cancer Therapy (NoCanTher)
Funding agency: European Commission , H2020, REF: GA 685795
WEB: NoCanTher 
MicroRNA based nanotherapies for the detection and treatment of muscular diseases (NanomiR)

Funding agency: EuronanoMed II (MINECO). REF: PCIN-2016-167
WEB: NanoMir

Diseño y evaluación de agentes terapéuticos y sensores basados en ARNs no codificantes y nanoestructuras (miRGold)
Funding agency: MINECO, REF: SAF2014-56763-R
Oligonucleotidos modificados en nanomedicina: deteccion de secuencias de acidos nucleicos e inhibicion de la expresion genica mediante arn interferente
Funding agency: MINECO, REF: SAF2010-15440
Multifunctional Nanotechnology for selective detection and Treatment of cancer (MULTIFUN)
Funding agency: European Commission , FP7, REF: 262943. The aim of the collaborative project MULTIFUN is to develop functionalized nanoparticles for the detection and treatment of breast and pancreatic cancer. 
WEB: Multifun